Heavitree Brewery 'A' Shares (HVTA)

Sector:

Tourism and Leisure Services

   Trade now with Barclays Stockbrokers   Trade now with Barclays   Sponsored by Barclays Stockbrokers

 220.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 230.00p
  • 52 Week Low: 220.00p
  • Currency: UK Pounds
  • Shares Issued: 273.48m
  • Volume: 0
  • Market Cap: £601.65m
  • RiskGrade: 37

Directors buy following Proximagen deal

Date: Thursday 05 Aug 2010

LONDON (ShareCast) - Three directors in AIM-quoted biotech sector consolidator Proximagen have added to their holdings following the company’s deal with BrainCells Inc for its sabcomeline programme.

The Proximagen share price was flat yesterday but the news of the share buying sparked it into life and it ended up 16.5p at 100p.

Chief executive Ken Mulvany, finance director James Hunter and non-exec Michael Ashton each bought 15,000 shares at an average price of 84p a share. The shares were bought on 4 and 5 August.

Mulvany owns 1.39% of Proximagen, while Hunter owns 20,000 shares and Ashton 41,384 shares.

BCI will pay Proximagen an up-front fee and milestone payments worth up to $51m for sabcomeline, as well as royalties on sales. However, most of this cash will not be paid for years and that assumes the clinical trials go as planned. BCI will own the worldwide rights to sabcomeline, which was acquired by Proximagen in February when it paid 6p a share for AIM-quoted Minster Pharmaceuticals, which valued the drug developer at £4.3m. Minster came with £3.5m in cash.

Sabcomeline is a treatment for cognitive decline in schizophrenia, which was licensed from GlaxoSmithKline. This is not a core area for Proximagen, which focuses on treatments for neurological conditions. BCI will be responsible for milestone and royalty payments to GSK, as well as the clinical development, regulatory filing and commercialisation of the drug. A phase II trial is planned.

In June 2009, Proximagen raised £49m at 140p a share. Proximagen still had £51m in cash and bank deposits at the end of May 2010. There was an outflow from operations of £3.5m in the year to May 2010. Proximagen is valued at £57.4m so there is little upside from its drugs recognised in the share price. Prior to today’s share price rise the company was trading at below cash.

Minnesota-based Upsher-Smith agreed a similar deal to the BCI one for PRX1, which is a programme for the symptomatic treatment of Parkinson’s disease based on an improved version of L-Dopa – a known treatment. The upfront and milestone payments alone could come to $232m (£117m). Again most of these payments are a long way off, although Upsher-Smith did invest $6m at 227p a share in October 2008.

Top Director Buys

eXpansys (XPS)
Director name: Mr Graham Dawber
Amount purchased: 339,000 @ 7.25p
Value: £24,578

Proximagen Group (PRX)
Director name: Mr James Douglas Hunter
Amount purchased: 15,000 @ 84.00p
Value: £12,600

Proximagen Group (PRX)
Director name: Mr Kenneth Mulvany
Amount purchased: 15,000 @ 84.00p
Value: £12,600

Proximagen Group (PRX)
Director name: Mr Michael Ashton
Amount purchased: 15,000 @ 84.00p
Value: £12,600

MS International (MSI)
Director name: Mr David Pyle
Amount purchased: 10,000 @ 121.50p
Value: £12,150


Top Director Sells

Heavitree.A (HVTA)
Director name: Mr Rodney J Glanville
Amount sold: 7,000 @ 170.00p
Value: £11,900

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HVTA Market Data

Currency UK Pounds
Share Price 220.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 230.00p
52 Week Low 220.00p
Volume 0
Shares Issued 273.48m
Market Cap £601.65m
RiskGrade 37

HVTA Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
31.76% below the market average31.76% below the market average31.76% below the market average31.76% below the market average31.76% below the market average
17.33% below the sector average17.33% below the sector average17.33% below the sector average17.33% below the sector average17.33% below the sector average
Price Trend
0.15% below the market average0.15% below the market average0.15% below the market average0.15% below the market average0.15% below the market average
5.13% above the sector average5.13% above the sector average5.13% above the sector average5.13% above the sector average5.13% above the sector average
Income
52.87% above the market average52.87% above the market average52.87% above the market average52.87% above the market average52.87% above the market average
36.00% above the sector average36.00% above the sector average36.00% above the sector average36.00% above the sector average36.00% above the sector average
Growth
41.31% above the market average41.31% above the market average41.31% above the market average41.31% above the market average41.31% above the market average
50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average

HVTA Dividends

  Latest Previous
  Interim Final
Ex-Div 18-Jul-19 21-Mar-19
Paid 02-Aug-19 18-Apr-19
Amount 3.67p 4.25p

Trades for --2019

Time Volume / Share Price
0 @ 0.000p

Top of Page